Testicular cancer is the most common neoplasia occurring in the young male population. The PEB (cisplatin, etoposide and bleomycin) adjuvant chemotherapy usually proposed after orchidectomy in non seminomatous tumours, and in metastatic seminomas, has improved the long-term survival of these patients. Following an azoospermic period, sperm cell recovery is generally observed after treatment delivery, but little is known about the genetic consequences on these new spermatozoa. To estimate the chromosomal consequences of this chemotherapy on sperm cells during the period of recovery of spermatogenesis, sperm cell aneuploidy was studied in testicular cancer patients, at 6-18 months after PEB adjuvant chemotherapy delivery, using fluorescence in-situ hybridization (FISH) of chromosomes 7, 16, 18, X and Y with specific DNA probes. A significant increase in the frequency of diploidy and disomy for chromosomes 16, 18 and XY was observed in treated patients compared with a healthy control group. Spermatozoa aneuploidy occurring during the spermatogenesis recovery period might be a possible side effect of the PEB regimen. Thus, practitioners should be advised to provide counselling about the need for an appropriate duration of contraception. Moreover, genetic counselling should be offered in cases of pregnancy occurring soon after the end of chemotherapy.
Introduction
studies or have small sample sizes which are not able to detect less than a 3-to 5-fold increase in relative risks (Meistrich, Testicular cancer is the most common neoplasia occurring in 1993). Moreover, few studies have assessed the genetic consethe young male population, and its incidence appears to be quences of chemotherapy on spermatozoa. Rather, they increasing (Adami et al., 1994; Forman and Møller, 1994) . In addressed different chemotherapy regimens and their results non seminomatous tumours (Culine et al., 1997; Sternberg, are conflicting, showing the presence (Jenderny and Röhrborn, 1998) , and in metastatic seminomas (Warde et al., 1996 (Warde et al., ), 1987 Genesca et al., 1990a,b; Brandriff et al., 1994 ; Monteil adjuvant chemotherapy proposed after orchidectomy has et al., 1997; Robbins et al., 1997; Martin et al., 1999) or improved the long-term survival of these patients. Chemoabsence (Jenderny et al., 1992; Martin et al., 1995 Martin et al., , 1997a ,b) therapy usually consists of two to four cycles of the PEB of chromosomal alterations. In the case of testicular cancer (cisplatin, etoposide and bleomycin) regimen, according to the chemotherapy, only one group has studied the effects of the stage of the neoplasia. Few studies have reported the effects PEB regimen on sperm chromosomes. In four patients who of PEB chemotherapy on spermatogenesis in patients treated provided sperm samples between 2 and 13 years after chemofor testicular cancer. Patients become azoospermic during therapy, neither structural (Martin et al., 1997b) nor numerical weeks following treatment initiation, but spermatogenesis does (Martin et al., 1997a) abnormalities were found. On the other not seem to be affected in the long term (Cullen et al., 1996;  hand, one patient investigated soon after the beginning of 4 Pont et al., 1996) . While spermatogenesis recovery is generally cycles of PEB regimen (at 59 and 366 days), showed a observed, little is known about the genetic consequences on significant increase in sperm chromosomal abnormalities these new spermatozoa. (Martin et al., 1999) . The incidence of congenital malformation does not appear Using fluorescence in-situ hybridization (FISH) of to be increased in offspring of male cancer patients following chemotherapy. However, published reports are either case chromosome-specific DNA probes, the aim of this study was to Orange CEP 18 alpha appeared yellow. The chromosome 18 probe Five patients with testicular tumours at the CECOS Midi-Pyrénées, was used as an internal control to distinguish between sex chromosome Male Sterility Center in Toulouse who provided sperm samples for disomy and diploidy. cryopreservation before PEB treatment, were recruited for the study.
To avoid scoring bias, the same stringent scoring criteria were used Sperm samples were obtained at 6-17 months after chemotherapy, by one examiner (P.D.M.) on both groups. Sperm nuclei were scored and frozen until analysis. All patients gave their informed consent as having two signals when they displayed two signals of equal size for the sperm chromosomes analysis. Semen specimens from five and intensity, separated by at least the diameter of one signal (Martin healthy fertile sperm volunteer donors were used as controls (mean and Rademaker, 1995) and well positioned within the sperm head. age 37.2 years; range: 32-45 years).
Overlapping spermatozoa or sperm heads without a well-defined The PEB chemotherapeutic regimen (based on body surface area) boundary were not evaluated. Nullisomies of one of the tested was 120 mg/m 2 etoposide and 20 mg/m 2 cisplatin from day 1 to day chromosomes were not directly scored and were considered as 5, and 30 mg bleomycin on days 2 and 9. This regimen was repeated equivalent to the incidence of disomies (Downie et al., 1997 ; Egozcue two, three or four times at monthly intervals according to the et al., 1997) . A total of 10 000 consecutive sperm nuclei were scored tumoral grade.
from each combination of probes. The data were analysed by the χ 2 test. A P-value Ͻ 0.05 was Sample preparation considered significant. After thawing, semen samples were washed twice in a buffer solution (0.1 mol/l Tris-HCl, pH 8.0) and, following the final centrifugation
Results
at 400 g, were resuspended in 0.5-2.0 ml buffer. One drop of the suspension was smeared onto a clean glass microscope slide and Clinical data, sperm counts and treatments are reported in allowed to air-dry. Slides were either stored in a slide box and kept Table I . Except for one patient (B) the differences in sperm at -20°C or used immediately in preparation for FISH. count before and after chemotherapy were quite moderate in
The slides were dehydrated through 70, 85 and 100% ethanol for the studied patients. Analysis of 20 000 sperm cells was carried CE ϭ carcinoembryonic; CT ϭ chemotherapy; FISH ϭ fluorescence in-situ hybridization; S ϭ seminoma. a decision was made to study the earliest period after chemofrequency of aneuploidy during the first 18 months following initiation of the PEB chemotherapy. therapy in which recovery of spermatogenesis is detected. As detection of chromosomal abnormalities has not been reported Among the drugs used, etoposide appears to be a good candidate for aneuploid sperm induction as it interacts with after the second year following PEB treatment (Martin et al., 1997a,b) , the current study was focused on the critical period topoisomerase II during anaphase I and II of meiosis. Topoisomerase II activity is required for removing regions of DNA from the recovery of spermatogenesis to the second-year threshold.
catenation between (sister and non-sister) chromatids. This decatenation enables segregation of homologous chromosomes The current study, using 7, 16, 18, X and Y -specific chromosome probes demonstrated a significant increase in and sister chromatids (Murray and Szostak 1985; Holm et al., 1989) . Etoposide inhibits topoisomerase II activity by forming sperm aneuploidy (disomy 16, 18, XY and diploidy) in treated patients compared with control men.
a DNA-topoisomerase II-drug ternary complex, and induces a non-disjunction of recombinant chromosomes (Rose et al., To date, only one other group has reported a study on sperm damage after PEB chemotherapy in patients treated for 1990) and of sister chromatids (Downes et al., 1991) . Experiments in vivo showed that etoposide treatment results in an testicular cancer. This group (Martin et al., 1997a ) studied disomy for chromosomes 1, 12, X, Y, XY and diploidy by increased risk of aneuploid germ cells, in mouse oocytes (Mailhes et al., 1994) and also in spermatocytes (Kallio and FISH in four testicular cancer patients both before and 2 to 13 years after treatment with PEB. These authors did not find Lahdetie, 1996) . Abnormal chromosome segregation has been shown with bleomycin in yeast (Sora et al., 1983; Käfer, 1990 ) any increased risk of numerical chromosomal abnormalities. Sperm karyotyping was used to confirm this result, and the and in Drosophila melanogaster (Traut, 1980) , but the main effect of the drug is the induction of DNA double-strand possibility of an increased risk of structural abnormalities in the same patients was excluded (Martin et al., 1997b) . However, breaks resulting in structural chromosome abnormalities, as shown in hamster primary embryonic cells (Xiao and Natarajan, in a patient submitted to four PEB cycles, the study of sperm cell chromosomes by FISH before, during (59 days) and after 1999) and in human lymphocytes (Ellard et al., 1995) . No increased risk of aneuploidy was shown with cisplatin (cis-(366 days) chemotherapy showed an increased aneuploidy, which is in agreement with the current results. In fact, a diamminodichloroplatinum II) in either male or female germ cells of D. melanogaster (Brodberg et al., 1983) or in murine significant increase of the XY disomy and of diploid sperm cells was noticed (Martin et al., 1999) . The current results led metaphase II oocytes (Higdon et al., 1992) . The impact of the drugs used is further demonstrated by to a similar observation showing a significant increase in the discrepancies between various chemotherapeutic regimens used Whatever the cause and duration of sperm aneuploidy, the consequences could be spontaneous abortion, stillbirth or birth in different cancers (Table III) . In two studies (Jenderny and Röhrborn, 1987; Genesca et al., 1990a) , interspecific defects in chromosomally abnormal children (Hassold et al., 1996) . In fact, under experimental conditions, no selection of fertilization of hamster eggs was used to show a significant increase in the incidence of stable structural chromosome chromosomally abnormal spermatozoa occurs during fertilization, and numerous studies (Genesca et al., 1990a,b; Brandriff abnormalities (deletions, translocations, inversions) . This was seen in the spermatozoa of two patients treated for non et al., 1994; Marchetti et al., 1999) have shown (by using several methods) that aneuploid spermatozoa are as competent seminoma testicular cancer by PVB (cis-platinum diaminedichloride, vinblastine, bleomycin) or PVB ϩ PEB, 2 and 5 as normal spermatozoa for fertilizing mouse oocytes. It is believed that patients must be informed of these facts, years after treatment, and also four additional patients, treated 5 to 18 years earlier by chemotherapy and/or radiotherapy for so that genetic counselling can be offered. With regard to PEB chemotherapy, while the hypothesis of a transient chromosomal sarcoma or Wilms' tumour (Genesca et al., 1990b) . Conversely, in the study of a PVB-treated testicular cancer patient (Jenderny side effect appears possible, more studies on sperm chromoet al., 1992) , no increase in chromosome structural abnormalitsomes are required before and during the follow-up of the ies was found. Indeed, the earliest studies are controversial treatment. Definitive conclusions will help practitioners in with regard to numerical chromosome aberrations. Some counselling about the necessity and duration of contraception reports claimed an increase in numeric chromosome anomalies after chemotherapy treatment, while a chromosomal examina- (Jenderny and Röhrborn, 1987; Genesca et al., 1990a ; Brandriff tion could be proposed in cases of pregnancy of these patients ' et al., 1994) , while others did not (Genesca et al., 1990b;  partners, soon after the end of chemotherapy. Jenderny et al., 1992) . All of these studies used the interspecific hamster test, and it is possible that the low number of sperm
